BravoVax CEO was Invited to Attend "2022 Vaccine Innovation Summit"

On June 1-2, 2022, the "2022 Vaccine Innovation Summit", jointly organized by Bio-industry Experts Association of Chengdu High-tech Zone and BioVally, was broadcast live online. The Summit focused on innovative design of vaccines, novel R&D technology and progress in clinical study. KOLs from Centers for Disease Control, academic institutions, and vaccine industries were invited to the Summit. Dr. Wu Ke, CEO of BravoBio, was invited and gave a keynote speech on "Key points of development of pan-Sarbecovirus vaccine". Around 70,000 audiences attended the Summit online.

Dr. Wu said, the Pan-Sarbecovirus vaccine may be the ultimate weapon for human society to return to normal, and the research and development work cannot be delayed.

In Dec. 2021, BravoBio signed strategic cooperation agreement with Jiang Shibo team of Fudan University and Fulgent Genetics to jointly develop pan-Sarbecovirus vaccine, aiming to prevent current and future global pandemics of SARS-like diseases, and to achieve the return of the normal state of human society.